Tumor markers in non-small cell lung cancer spine metastasis: an assessment of prognosis and overall survival

被引:0
作者
Foresi, Brian [1 ]
Shah, Aakash [2 ]
Meade, Seth [2 ]
Krishnaney, Ajit [3 ]
机构
[1] Northeast Ohio Med Univ NEOMED, Coll Med, Rootstown, OH 44272 USA
[2] Case Western Reserve Univ, Coll Med, Cleveland, OH USA
[3] Cleveland Clin, Dept Neurosurg, Cleveland, OH USA
关键词
Non-small cell lung cancer; Metastasis; Spine; Tumor markers; Prognosis; Overall survival; PREOPERATIVE EVALUATION; SCORING SYSTEM; BONE;
D O I
10.1007/s00586-024-08447-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
PurposeThe identification of gene mutations in the modern medical workup of metastatic spine tumors has become more common but has not been highly utilized in surgical planning. Potential utility of these genetic markers as surrogates for cancer behavior in current prognosis scoring systems and overall survival (OS) remains underexplored in existing literature. This study seeks to investigate the association of frequently identified tumor markers, EGFR, ALK, and PD-L1, in metastatic non-small cell lung cancer (NSCLC) to the spine with Tokuhashi prognosis scoring and OS.MethodsPatients with NSCLC metastasis to spine were identified through chart review. EGFR, ALK, and PD-L1 wild type vs. mutant type were identified from targeted chemotherapy genetic testing. Multiple linear regression was performed to assess gene profile contributions to Tokuhashi score. Cox Proportional Hazards models were generated for each tumor marker to assess the relationship between each marker and OS.ResultsA total of 119 patients with NSCLC spine metastasis were identified. We employed a multiple linear regression analysis to investigate the influence of EGFR, ALK, and PD-L1 genotypes on the Tokuhashi score, revealing statistically significant relationships overall (p = 0.002). Individual genotype contributions include EGFR as a non-significant contributor (p = 0.269) and ALK and PD-L1 as significant contributors (p = 0.037 and p = 0.001 respectively). Overall survival was not significantly associated with tumor marker profiles through Kaplan-Meier analysis (p = 0.46) or by multivariable analysis (p = 0.108).ConclusionALK and PD-L1 were significantly associated with Tokuhashi score while EGFR was not. Tumor markers alone were not predictive of OS. These findings indicate that genetic markers found in NSCLC metastases to the spine may demonstrate prognostic value. Therefore, employing standard tumor markers could enhance the identification of appropriate surgical candidates, although they demonstrate limited effectiveness in predicting overall survival.
引用
收藏
页码:4346 / 4352
页数:7
相关论文
共 29 条
  • [1] Predicting survival for metastatic spine disease: a comparison of nine scoring systems
    Ahmed, A. Karim
    Goodwin, C. Rory
    Heravi, Amir
    Kim, Rachel
    Abu-Bonsrah, Nancy
    Sankey, Eric
    Kerekes, Daniel
    Ramos, Rafael De la Garza
    Schwab, Joseph
    Sciubba, Daniel M.
    [J]. SPINE JOURNAL, 2018, 18 (10) : 1804 - 1814
  • [2] [Anonymous], Cancer of the lung and bronchus - cancer stat facts
  • [3] Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
    Britschgi, Christian
    Addeo, Alfredo
    Rechsteiner, Markus
    Delaloye, Raphael
    Frueh, Martin
    Metro, Giulio
    Banini, Marco
    Gautschi, Oliver
    Rothschild, Sacha I.
    Wild, Peter J.
    Banna, Giuseppe L.
    Curioni-Fontecedro, Alessandra
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
    Brouns, Anita J. W. M.
    van Veelen, Ard
    Veerman, G. D. Marijn
    Steendam, Christi
    Dursun, Safiye
    van der Leest, Cor
    Croes, Sander
    Dingemans, Anne-Marie C.
    Hendriks, Lizza E. L.
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05):
  • [5] Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
    D'Antonio, Chiara
    Passaro, Antonio
    Gori, Bruno
    Del Signore, Ester
    Migliorino, Maria Rita
    Ricciardi, Serena
    Fulvi, Alberto
    de Marinis, Filippo
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (03) : 101 - 114
  • [6] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
    Dantoing, Edouard
    Piton, Nicolas
    Salaun, Mathieu
    Thiberville, Luc
    Guisier, Florian
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [7] ALK-rearrangement in non-small-cell lung cancer (NSCLC)
    Du, Xue
    Shao, Yun
    Qin, Hai-Feng
    Tai, Yan-Hong
    Gao, Hong-Jun
    [J]. THORACIC CANCER, 2018, 9 (04) : 423 - 430
  • [8] Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis
    Eichhorn, Florian
    Kriegsmann, Mark
    Klotz, Laura V.
    Kriegsmann, Katharina
    Muley, Thomas
    Zgorzelski, Christiane
    Christopoulos, Petros
    Winter, Hauke
    Eichhorn, Martin E.
    [J]. CANCERS, 2021, 13 (09)
  • [9] Comparison of Direct Sequencing, Real-Time PCR-High Resolution Melt (PCR-HRM) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) Analysis for Genotyping of Common Thiopurine Intolerant Variant Alleles NUDT15 c.415C>T and TPMT c.719A>G (TPMT*3C)
    Fong, Wai-Ying
    Ho, Chi-Chun
    Poon, Wing-Tat
    [J]. DIAGNOSTICS, 2017, 7 (02):
  • [10] Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US
    Ganti, Apar Kishor
    Klein, Alyssa B.
    Cotarla, Ion
    Seal, Brian
    Chou, Engels
    [J]. JAMA ONCOLOGY, 2021, 7 (12) : 1824 - 1832